Ranibizumab News and Research

RSS
NEI-funded study analyzes outcomes of anti-VEGF therapy for AMD

NEI-funded study analyzes outcomes of anti-VEGF therapy for AMD

Added benefit of aflibercept not proven in myopic choroidal neovascularisation

Added benefit of aflibercept not proven in myopic choroidal neovascularisation

New study reveals better treatment options for proliferative diabetic retinopathy

New study reveals better treatment options for proliferative diabetic retinopathy

Researchers find ranibizumab drug as effective alternative to laser therapy for treating diabetic retinopathy

Researchers find ranibizumab drug as effective alternative to laser therapy for treating diabetic retinopathy

Ranibizumab may become reasonable treatment alternative for patients with proliferative diabetic retinopathy

Ranibizumab may become reasonable treatment alternative for patients with proliferative diabetic retinopathy

NAM announces election of three new members from UC San Diego School of Medicine

NAM announces election of three new members from UC San Diego School of Medicine

Risk for endophthalmitis no higher with Avastin, finds study

Risk for endophthalmitis no higher with Avastin, finds study

Macular atrophy predicts vision in ranibizumab-treated exudative AMD patients

Macular atrophy predicts vision in ranibizumab-treated exudative AMD patients

Darapladib shows promise in diabetic macular oedema

Darapladib shows promise in diabetic macular oedema

ORT incidence increases in nAMD despite anti-VEGF treatment

ORT incidence increases in nAMD despite anti-VEGF treatment

IQWiG examines added benefit of aflibercept in macular oedema after branch retinal vein occlusion

IQWiG examines added benefit of aflibercept in macular oedema after branch retinal vein occlusion

Study could offer new way to treat, prevent diabetes-associated blindness

Study could offer new way to treat, prevent diabetes-associated blindness

Anti-VEGF therapy benefits in wet AMD not sustained

Anti-VEGF therapy benefits in wet AMD not sustained

No added benefit with pazopanib over ranibizumab for neovascular AMD

No added benefit with pazopanib over ranibizumab for neovascular AMD

Similar diabetic macular oedema outcomes with deferred vs prompt laser therapy

Similar diabetic macular oedema outcomes with deferred vs prompt laser therapy

Risk factors predict geographic atrophy after anti-VEGF treatment of RAP

Risk factors predict geographic atrophy after anti-VEGF treatment of RAP

New edition of WHO Essential Medicines List includes new treatments for hepatitis C, cancers and multi-drug TB

New edition of WHO Essential Medicines List includes new treatments for hepatitis C, cancers and multi-drug TB

WHO moves to improve access to lifesaving medicines for hepatitis C, Drug-resistant TB and cancers

WHO moves to improve access to lifesaving medicines for hepatitis C, Drug-resistant TB and cancers

Clinical study comparing effectiveness of three standard treatments for DME published in NEJM

Clinical study comparing effectiveness of three standard treatments for DME published in NEJM

Ranibizumab drug reverses diabetes-related blindness

Ranibizumab drug reverses diabetes-related blindness